US 12,201,727 B2
Sustained release formulations of Dysoxylum binefacterum
Sonali Sandip Bharate, Jammu (IN); Vikas Kumar, Jammu (IN); Mehak Gupta, Jammu (IN); Sumit Gandhi, Jammu (IN); Ajay Kumar, Jammu (IN); Sandip Bibishan Bharate, Jammu (IN); and Ram Vishwakarma, Jammu (IN)
Assigned to COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH, New Delhi (IN)
Filed by COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH, New Delhi (IN)
Filed on Oct. 13, 2023, as Appl. No. 18/380,054.
Application 18/380,054 is a division of application No. 17/046,007, granted, now 11,878,075, previously published as PCT/IN2019/050313, filed on Apr. 18, 2019.
Claims priority of application No. 201811014818 (IN), filed on Apr. 19, 2018.
Prior Publication US 2024/0041772 A1, Feb. 8, 2024
Int. Cl. A61K 9/16 (2006.01); A61K 36/58 (2006.01)
CPC A61K 9/1635 (2013.01) [A61K 9/1652 (2013.01); A61K 36/58 (2013.01)] 8 Claims
OG exemplary drawing
 
1. A method of treating an rheumatoid arthritis in a patient, the method comprising: administering a sustained release formulation to a patient, the sustained release formulation comprising:
30-60% w/w of an extract or fraction obtained from leaves of Dysoxylum binectariferum;
25-50% w/w of a hydroxypropylmethylcellulose;
5-15% w/w of sodium alginate; and
a binder;
wherein the extract or fraction comprises at least 2% w/w of Rohitukine and at least 1% w/w of Schumaniofioside A.